First experience of using nebulized tobramycin in patients with acute exacerbation of bronchiectasis
https://doi.org/10.18093/0869-0189-2011-0-4-133-138
Abstract
First experience of using nebulized tobramycin in patients with acute exacerbation of bronchiectasis.
About the Authors
S. N. Avdeev
ФГУ "НИИ пульмонологии" ФМБА России
Russian Federation
Russian Federation
N. А. Karchevskaya
ФГУ "НИИ пульмонологии" ФМБА России
Russian Federation
Russian Federation
References
1. Reid L.M. Reduction in bronchial subdivision in bronchiectasis. Thorax 1950; 5: 233–247.
2. Barker A.F. Bronchiectasis. N. Engl. J. Med. 2002, 346: 1383–1393.
3. Pasteur M.C., Helliwell S.M., Houghton S.J. et al. An investigation into causative factors in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 2000; 162: 1277–1284.
4. Cole P.J. Inflammation: a two-edged sword- the model of bronchiectais. Eur. J. Respir. Dis. 1986; Suppl. 147: 6–15.
5. Finklea J.D., Khan G., Thomas S. et al. Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis. Respir. Med. 2010; 104: 816–821.
6. Alzeer A.H., Masood M., Jani Basha S. et al. Survival of brochiectatic patients with respiratory failure in ICU. BMC Pulm. Med. 2007; 7: 17.
7. Dupont M., Gacouin A., Lena H. et al. Survival of patients with bronchiectasis after the first ICU stay for respiratory failure. Chest 2004; 125: 1815–1820.
8. Haworth C.S. Antibiotic treatment strategies in adults with bronchiectasis. Eur. Respir. Mon. 2011; 52, 211–222.
9. Vendrell M., de Gracia J., Olveira C. et al. Diagnosis and treatment of bronchiectasis. Arch. Bronconeumol. 2008; 44: 629–640.
10. Ho P.L., Chan K.N., Ip M.S.M. et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest 1998; 114: 1594–1598.
11. Evans S.A., Turner S.M., Bosch B.J. et al. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur. Respir. J. 1996; 9: 1601–1604.
12. Wilson C.B., Jones P.W., O'Leary C.J. et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur. Respir. J. 1997; 10: 1754–1760.
13. Weycker D., Edelsberg J., Oster G. et al. Prevalence and economic burden of bronchiectasis. Clin. Pulm. Med. 2005; 12: 205–209.
14. Bilton D., Henig N., Morrissey B., Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006; 130; 1503–1510.
15. Wood G.C., Boucher B.A. Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy 2000; 20: 166–181.
16. Ramsey B.W., Pepe M.S., Quan J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 1999; 340: 23–30.
17. Hodson M.E., Gallagher C.G., Govan J.R.W. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 2002; 20: 658–664.
18. Moss R.B. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121: 55–63.
19. Cheer S.M., Waugh J., Noble S. Inhaled tobramycin (TOBI): A review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003; 63: 2501–2520.
20. Carcas A.J., Garcia)Statue J.L., Zapater P., Frias)Iniesta J. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin. Pharmacol. Ther. 1999; 65: 245–250.
21. Goldstein I., Wallet F., Nicolas)Robin A. et al. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am. J. Respir. Crit. Care Med. 2002; 166: 1375–1381.
22. Makhoul I.R., Merzbach D., Lichtig C., Berant M. Antibiotic treatment of experimental Pseudomonas aeruginosa pneumonia in guinea pigs: Comparison of aerosol and systemic administration. J. Infect. Dis. 1993; 168: 1296–1299.
23. Kahler D.A., Schowengerdt K.O., Fricker F.J. et al. Toxic serum trough concentrations after administration of nebulized tobramycin. Pharmacotherapy 2003; 23: 543–545.
24. Angrill J., Agusti C., de Celis R. et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57: 15–19.
25. Murray P.R., Washington J.A. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin. Proc. 1975; 50: 339–344.
26. Palmer L.B., Smaldone G.C., Simon S.R. et al. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit. Care Med. 1998; 26: 31–39.
27. Goldstein I., Chastre J., Rouby J.J. Novel and innovative strategies to treat ventilator-associated pneumonia: optimizing the duration of therapy and nebulizing antimicrobial agents. Semin. Respir. Crit. Care Med. 2006; 27: 82–91.
28. Geller D.E., Pitlick W.H., Nardella P.A. et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219–226.
29. Le Conte P., Potel G., Peltier P. et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am. Rev. Respir. Dis. 1993; 147: 1279–1282.
30. Ghannam D.E., Rodriguez G.H., Raad I.I., Safdar A. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur. J. Clin. Microbiol. Infect. Dis. 2009; 28: 253–259.
31. Ilowite J.S., Gorvoy J.D., Smaldone G.C. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am. Rev. Respir. Dis. 1987; 136: 1445–1449.
32. Dhand R. The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir. Care 2007; 52: 866–884.
33. Conrad D.J. The clinical use of aerosolized antibiotics. Clin. Pulm. Med. 2003; 10: 201–207.
34. Chuchalin A., Amelina E., Bianco F. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements. Pulm. Pharm. Ther. 2009; 22: 526–532.
35. Knowles M.R., Robinson J.M., Wood R.E. et al. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease control subjects. J. Clin. Invest. 1997; 100: 2588–2595.
36. Barker A.F., Couch L., Fiel S.B. et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. 2000; 162: 481–485.
37. Couch L.A. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001; 120 (Suppl.): 114S–117S.
38. Scheinberg P., Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005; 127: 1420–1426.
39. Study to See if AZLI (an Inhaled Antibiotic) is Effective in Treating Adults With Non-CF Bronchiectasis – AIR-BX2. http://clinicaltrials.gov/ct2/show/NCT01314716.
40. Bilton D., Bruinenberg P., Otulana B. et al. Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum pseudomonas aeruginosa density in CF and non-CF bronchiectasis. Am. J. Respir. Crit. Care Med. 2009; 179: A3214.
41. O'Donnell A.E., Swarnakar R., Yahina L. et al. A placebocontrolled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectatic patients with chronic Pseudomonas aeruginosa lung infection. Eur. Respir. J. 2009; 34: 231S.
Review
For citations:
Avdeev S.N., Karchevskaya N.А. First experience of using nebulized tobramycin in patients with acute exacerbation of bronchiectasis. PULMONOLOGIYA. 2011;(4):133-138. (In Russ.) https://doi.org/10.18093/0869-0189-2011-0-4-133-138
Views:
681
Email this article 